Tebentafusp increases overall survival in previously untreated metastatic uveal melanoma

Longer overall survival was seen in patients with previously untreated metastatic uveal melanoma treated with tebentafusp compared to patients treated with control therapy, according to a study published in the New England Journal of Medicine.

In this open-label, phase 3 trial, 378 patients with metastatic uveal melanoma were randomly assigned to either the tebentafusp group (252 patients) or the investigator’s choice of therapy (126 patients).

In the intention-to-treat population, overall survival at 1 year in the tebentafusp and control groups was 73% and 59%, respectively. Progression-free survival at 6 months was 31% and 19%, respectively.

In patients in the tebentafusp group, the most common treatment-related adverse events included cytokine-mediated events and skin-related events; 2% of patients discontinued the trial due to adverse events. The incidence and severity of these events decreased after the first 3 or 4 doses.

Reference
Nathan P, Hassel JC, Rutkowski P, et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021;385:1196-1206. DOI: 10.1056/NEJMoa2103485